Merck & Co., Inc. (MRK) on Decifer

Decifer ranks MRK number 137 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 18% and those returns have been improving.
• Revenue is expected to grow about 5% a year, profits grew 8% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong returns near 18% and steady high margins make it a high quality business, but expected revenue growth of about 5% and no worldview role cap the upside.

The current read

The evidence on MRK lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Merck & Co., Inc. sits in the large-cap pharma layer of the Healthcare, Biotech & Devices story.

Read the full MRK research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.